Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment.
The Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.